GENE ONLINE|News &
Opinion
Blog

2020-07-17| PartnerAsia-Pacific

ITALY AT BIO ASIA TAIWAN 2020 – ONLINE

by GeneOnline
Share To

ITALY will once more be part of this trade show, at BIO ASIA TAIWAN 2020 – ONLINE.

The Italian pavilion, organized by ITA – Italian Trade Agency – and Italian Ministry of Foreign Affairs and International Cooperation will feature a delegation of 7 leading Italian biotech companies that encompass new biopharma, 3D medical printing, biotech services and bioindustry park.

3DIFIC S.r.l., a medical 3d printing company. They focus on a deep interaction with surgeons to understand precisely their necessities. They support doctors, scientists, and students to provide doctors with any patient-specific device they want.

The BIOINDUSTRY PARK SILVANO FUMERO S.p.a. which is located in the Piedmont region. The cluster of Piedmont gathers about 100 companies, research centers, R&D organizations and academic institutions in the healthcare sector. It has acted as a system integrator for the development of Life Sciences since its creation in 1998. Connect with them to find out about those companies and the Bioindustry Park.

In recent years IBSA FARMACEUTICI S.r.l. Italia has increased, becoming a significant economic and scientific company in the Italian pharmaceutical sector. Research and Development activities use advanced technology to study innovative methods for administering drugs. Today IBSA Farmaceutici Italia guarantees a vast number of products, ranging from people’s wellbeing to care and prevention, and covers 12 main therapeutic areas: Cardiometabolic, Dermatology, Dermo-aesthetic, Endocrinology, Human Reproduction, Osteoarticular, Pain and Inflammation, Respiratory, Urology, Ophthalmics, Otorhinolaryngology and Consumer Health.

For biopharmaceutical and med-tech companies that want to adopt global business development strategy, PHARMA & BIOTECH ADVISORS S.r.l. from Italy provides clients to solve their problems in strategy, operations, organization and change. Especially in advising firms in-licensing and alliances, portfolio management and emerging therapeutic/technological areas.

On the cell biotechnology field, REMEMBRANE S.r.l., an ISO 9001:2015 certified European SME. Its technology includes envisaging the cell membrane network and its lipid composition as a cornerstone of cell physiology. Remembrane designs, develops, and manufactures customised GMP-grade membrane-targeting Lipid Mixtures commercialized under the brand name Refeed.

SYNAPTICOM S.r.l.‘s patented active ingredients are supported by preclinical and clinical research and combined with innovative formulas, which are now widely used in therapy. The research results generated a “Drug-non-Drug” product platform registered as cosmetics and supplements, adding higher scientific value, thereby opening up a whole new market. Their most advanced pharmaceutical technology enables them to improve the bioavailability and effectiveness of the preparation.

VERA SALUS RICERCA S.r.l.’s an innovative biopharma company whose core capability is to discover best-in-class drug candidates that originated from natural compounds. Research is led by Prof. Giovanni Pitari from T. Jefferson University of Philadelphia, in collaboration with the Italian National Council for Research (CNR).

It is exciting to find out more about them in company presentations or virtual exhibitions during BIO Asia-Taiwan. You may also connect with their CEOs and executives during the one-on-one partnering event from July 22 to 26.

* Those Italian companies will be on July 24 in the company presentation section according to the schedule below!

24th, July, 2020

19:30 – 19:40 Vera Salus Ricerca S.r.l.
19:40 – 19:50 3DIFIC S.r.l.
19:50 – 20:00 Bioindustry Park Silvano Fumero S.p.a.
20:00 – 20:10 IBSA Farmaceutici S.r.l.
20:10 – 20:20 Pharma & Biotech Advisors S.r.l.
20:20 – 20:30 Remembrane S.r.l.
20:30 – 20:40 Synapticom S.r.l.

 

Make sure to sign up and check out those companies at the company presentation!

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
BIO Asia-Taiwan 2022: Looking for the Exit; Startup Considerations and Strategies
2022-07-28
BIO Asia-Taiwan 2022: Top iPS Cell Technologies at Affordable Prices – Keynote by Nobel Laureate Shinya Yamanaka
2022-07-28
Reinvigorating the Asian Biomedical Ecosystem With BIO Asia-Taiwan 2022
2022-07-26
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!